Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.

Merck & Co. Inc. has launched Renflexis (infliximab-abda), the company announced July 24, marking the first time two biosimilars will compete against a brand drug in the US. Renflexis is the second biosimilar version of Johnson & Johnson's blockbuster anti-TNF Remicade (infliximab) to reach the US market behind Pfizer Inc.'s Inflectra (infliximab-dyyb).

Merck appears to be competing aggressively on price, which will be welcome news to payers. The company set the wholesale...

Welcome to Scrip

Create an account to read this article

More from New Products

More from Scrip

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.